Most Recent
Generic drug maker Alphapharm has lost another bid for documents from Sanofi-Aventis in advance of a hearing on Sanofi's interlocutory application seeking to block the generic drug maker from listing its injector pen on the Pharmaceutical Benefits Scheme.
A four-day trial against online ticket reseller Viagogo kicked off Monday, with the ACCC describing how the site misled consumers by falsely claiming it was an official ticket vendor, hitting them with a booking fee of around 28 per cent along the way.
A group representing patent and trade mark lawyers is seeking to intervene in a high-stakes appeal over computer software patents.
Food manufacturer Goodman Fielder has shot back against claims by rival Conga Foods that six of its trade marks for pasta products should be deregistered for non-use.
A US sports news website founded by former Yankees shortstop Derek Jeter featuring content by athletes has filed a lawsuit alleging an Australian sports site has violated its IP.
Preparations for a December trial between Merck Sharp & Dohme Corporation and Wyeth over four patents for the pneumococcal disease vaccine are underway, and a panel of experts will feature prominently in the high-stakes hearing over the world's best-selling vaccine.
Generic drug company Alphapharm has lost a bid for documents it claimed would show Sanofi-Aventis suspected as early as 2015 that patents for one of its injector pens may be invalid.
A Federal Court judge has put an appeal by Aristocrat of an IP Australia ruling that revoked four of its gaming patents on hold pending the outcomes of two highly anticipated cases over the patentability of computer software.
ObjectiVision has presented a "limited" and "debatable" case that its source code for a glaucoma testing device was copied, the Federal Court heard Thursday as the trial in a four-year spat with the University of Sydney over IP rights came to a close.
Ophthalmic diagnostic device manufacturer ObjectiVision has made its final pitch to the Federal Court at the end of trial in a long-running intellectual property and contract dispute with the University of Sydney, saying in closing submissions that the school had run a "curious" case.